Status:
COMPLETED
Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy
Lead Sponsor:
Yong Huo
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This study was a feasibility trial that was designed to provide preliminary observations and generate hypotheses for future studies. The aim of the study is to estimate the difference of arachidonic a...
Detailed Description
This is a randomized, open labeled, active-controlled pilot study to estimate the difference of arachidonic acid induced platelet aggregation rate between ticagrelor monotherapy and aspirin/ticagrelor...
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study specific procedures.
- Aged \>18 years.
- Documented stable coronary artery disease.
- Currently receiving dual-antiplatelet therapy with aspirin 100mg/d and clopidogrel 75mg/d.
Exclusion
- History of acute coronary syndrome within 12 months of screening.
- History of percutaneous coronary intervention within 12 months of screening.
- Any indication (eg, atrial fibrillation,prosthetic heart valve, or coronary stent) for antithrombotic therapy(eg, warfarin, clopidogrel, or aspirin dose other than 75 to 100 mg/during the study period).
- AA induced platelet aggregation rate \>20% on aspirin+clopidogrel measured by light transmission platelet aggregation test with the past 3 months.
- Congestive heart failure or left ventricular ejection fraction \<35%.
- Forced expiratory volume in the first second forced vital capacity below the lower limits of normal.
- Bleeding diathesis or severe pulmonary disease.
- Active pathological bleeding.
- History of intracranial hemorrhage.
- Hypersensitivity to ticagrelor or any of the excipients.
- Severe hepatic impairment.
- Pregnancy.
- Current smoking.
- Platelet count \<100 000/mm3 or hemoglobin \<10 g/dL.
- HemoglobinA1c \>10%.
- History of drug addiction or alcohol abuse in the past 2 years.
- Need for nonsteroidal anti-inflammatory drug.
- Creatinine clearance\<30 mL/min.
- Concomitant therapy with moderate or strong cytochrome P450 3A inhibitors, substrates, or strong cytochrome P450 3A inducers.
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT02219412
Start Date
August 1 2014
End Date
August 1 2015
Last Update
June 21 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, China, 100034